We report two cases of severe ulcerative cutaneous chronic GVHD (cGVHD) that involved areas of sensory loss. The report highlights the importance of meticulous wound care and injury prevention measures to reduce the risk of this complication.
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Patient #1 is a 56-year-old African-American female who received an allogeneic transplant using matched related donor PBSCs in February 2009 as treatment for stage IVB diffuse large B-cell lymphoma who had failed initial therapy with R-CHOP in 2005, and then relapsed after a salvage regimen of rituximab, ifosphamide, cisplatin and etoposide followed by carmustine, etoposide, cytosine arabinoside, melphalan and rituximab with autologous SCT in 2006. Before her allogeneic transplant, she received fully ablative conditioning with 60 mg/kg/day for 2 days of CY and TBI (1200 cGy), and tacrolimus (targeted to 10 μg/L) and methotrexate (5 mg/m 2 on day +1, +6, +9 and +11) were used as GVHD prophylaxis. Neutrophil and platelet engraftment were on days 17 and 11, respectively and blood STRs confirmed 100% donor chimerism by day 17. On day 31 she developed, grade III acute GVHD with diffuse rash, liver enzyme elevation and diarrhea; colonoscopy and biopsy confirmed acute GVHD (aGVHD). With tapering steroid therapy, aGvHD improved but she continued on 10 mg prednisone daily.
From day 100 onward, she complained of sensory loss of subacute onset below both knees. An electron myography and nerve conduction (EMG-NC) study revealed decreased sensory responses in the right sural nerve and superficial peroneal nerve; but a left-sided study could not be performed owing to extensive and multiple cutaneous ulcers that developed from day 150 onward (Figure 1 ). Although the patient had received XRT (36 cGy over 20 fractions) to a left inguinal mass in 2006, no cause for the bilateral neuropathy could be determined; however, the histology of biopsies from the ulcers was consistent with that of GVHD. Subsequently, four apparently identical ulcers appeared on the right leg. Oral prednisone was continued at 10 mg and she was given standard wound care. Although these lesions have persisted for~3 years, they are slowly improving without surgical intervention. 1 At her 60-month follow-up, the patient remains in CR. Patient #2 is a 24-year-old Caucasian female who received an HLA-matched related donor PBSC transplant in August 2009 after entering CR2 of AML with diploid cytogenetics. Conditioning was with BU/CY (BU 0.8 mg/kg every 6 h × 4days with blood levels, CY 60 mg/kg/day for 2 days) and she received tacrolimus (targeted to 10 μg/L) and MTX (5 mg/m 2 on day +1, +6, +9 and +11) as GVHD prophylaxis. Following engraftment, she developed grade I aGVHD that resolved after treatment with prednisone. She had no cGvHD. Unfortunately, 35 months later, she relapsed with isolated meningeal disease and a left ileopsoas granulocytic sarcoma (GS), which produced a motor deficit and sensory loss affecting the L4/5 nerve root distribution (left upper lateral thigh and knee). BM biopsy was negative for disease. She received fludarabine, cytosine arabinoside and idarubicin in conjunction with serial intrathecal arabinoside and achieved complete resolution of her CNS and GS disease. She then received 900 cGy of external beam radiation to the site of previous GS. Her motor weakness improved but the sensory loss persisted. She received an HLA-matched (10/10) unrelated donor PBSC transplant in December 2012 with a myeloablative preparative regimen of 60 mg/kg/day for 2 days CY and TBI (1200 cGy in four fractions) with alemtuzumab (10 mg on day − 6, − 5 and − 4) and tacrolimus (targeted to 10 μg/L) as GVHD prophylaxis. Neutrophil engraftment occurred on day 12 and was followed on day 16 by grade III aGvHD involving the skin, liver and gut. Her GVHD responded to prednisone but she required a maintenance dose of 20 mg/day and she developed limited cGVHD involving skin that progressed to multiple full thickness punch ulcers~1.5 cm × 1.5 cm × 1 cm each on the medial aspect of the upper thigh and left knee that were compatible with GVHD on biopsy (Figure 2) . EMG-NC studies confirmed continued sensory loss in the affected region. With daily prograf (1.5 mg) and prednisone (20 mg) her cGVHD was well controlled and her ulcers healed over the ensuing 6 months with conservative wound care measures and bracing of the left knee. Although she remained in CR, she presented on day +320 with severe hypotension and sepsis, associated with a recommencement of her i.v. narcotic abuse. She died on day 320 after the second transplant.
We report two patients in whom neuropathy and sensory loss resulted in cGVHD-associated full thickness skin ulcers that were slow to heal. These ulcers appeared similar to the 'venous ulcers' seen in patients with chronic venous insufficiency or sickle cell disease. It is likely that the neuropathy leads to non-perceived repetitive trauma, and exacerbates the inadequate blood supply associated with cGVHD. Schlossberg et al. 2 reported two cases of severe bilateral leg ulcers following treatment of skin GVHD with thalidomide. Although these lesions were present before initiating thalidomide, they were exacerbated by the drug, and it is possible that this worsening was a consequence of thalidomide-associated sensory neuropathy.
Although these ulcers ultimately healed in one and are progressively improving in the other with continued GVHD treatment, wound care and skin protection from repeated trauma was significant, and it may be prudent to initiate earlier protective measures in patients who suffer from both peripheral sensory neuropathy and cGVHD. Conversely, the development of ulceration in patients suffering from cGVHD should lead physicians to exclude the presence of a concomitant sensory neuropathy.
